Tislelizumab

Generic Name: Tislelizumab

Brand Names: Tevimbra, Tizveni

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1858168-59-8

Unique Ingredient Identifier: 0KVO411B3N

Background: Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication: ⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Associated Conditions: -

Associated Therapies: -

Clinical Trials

PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy